Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia.

[1]  Joseph A. DiGiuseppe,et al.  Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy , 2017, Leukemia.

[2]  Marc S. Tyndel,et al.  Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. , 2017, Blood.

[3]  S. Miyano,et al.  Somatic mosaicism in chronic myeloid leukemia in remission. , 2016, Blood.

[4]  Gun Ho Jang,et al.  A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns , 2016, Nature.

[5]  A. Green,et al.  Pathogenesis of Myeloproliferative Disorders. , 2016, Annual review of pathology.

[6]  J. Bourhis,et al.  Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation , 2016, Oncotarget.

[7]  A. Bennaceur-Griscelli,et al.  Donor Dependent Variations in Hematopoietic Differentiation among Embryonic and Induced Pluripotent Stem Cell Lines , 2016, PloS one.

[8]  M. Stratton,et al.  Clock-like mutational processes in human somatic cells , 2015, Nature Genetics.

[9]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[10]  Julien Pontis,et al.  The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia. , 2015, Experimental hematology.

[11]  Marcos González,et al.  Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles. , 2015, Leukemia research.

[12]  G. Martinelli,et al.  Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia. , 2015, Clinical lymphoma, myeloma & leukemia.

[13]  C. Walsh,et al.  Cell Lineage Analysis in Human Brain Using Endogenous Retroelements , 2015, Neuron.

[14]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[15]  Christopher A. Miller,et al.  The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML , 2014, Nature.

[16]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[17]  Joshua F. McMichael,et al.  Age-related cancer mutations associated with clonal hematopoietic expansion , 2014, Nature Medicine.

[18]  A. Kohlmann,et al.  Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status , 2014, Leukemia.

[19]  Asif U. Tamuri,et al.  Genome sequencing of normal cells reveals developmental lineages and mutational processes , 2014, Nature.

[20]  Christian Beisel,et al.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. , 2014, Blood.

[21]  Lincoln D. Stein,et al.  Identification of pre-leukemic hematopoietic stem cells in acute leukemia , 2014, Nature.

[22]  P. Boutouyrie,et al.  Forearm ischemia decreases endothelial colony-forming cell angiogenic potential. , 2014, Cytotherapy.

[23]  Curt I Civin,et al.  Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. , 2013, Blood.

[24]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[25]  Francisco Cervantes,et al.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.

[26]  C. Wallington-Beddoe,et al.  Oncogenic properties of sphingosine kinases in haematological malignancies , 2013, British journal of haematology.

[27]  Martin C. Müller,et al.  Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. , 2013, Blood.

[28]  I. Weissman,et al.  Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia , 2012, Science Translational Medicine.

[29]  Joshua F. McMichael,et al.  The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.

[30]  A. Bashashati,et al.  Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer , 2012, Genome research.

[31]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[32]  David A. Williams,et al.  Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. , 2012, Blood.

[33]  C. Preudhomme,et al.  Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia , 2011, Leukemia.

[34]  A. Bennaceur-Griscelli,et al.  Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. , 2011, Blood.

[35]  E. Nigg,et al.  Probing the in vivo function of Mad1:C‐Mad2 in the spindle assembly checkpoint , 2011, The EMBO journal.

[36]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[37]  Michael A McDevitt,et al.  CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. , 2011, Blood.

[38]  B. Ebert,et al.  The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. , 2011, Blood.

[39]  A. Kohlmann,et al.  A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases , 2011, Leukemia.

[40]  C. Eaves,et al.  Insights into the stem cells of chronic myeloid leukemia , 2010, Leukemia.

[41]  B. Péault,et al.  Embryonic origin of human hematopoiesis. , 2010, The International journal of developmental biology.

[42]  T. Skorski,et al.  Chronic myeloid leukemia: mechanisms of blastic transformation. , 2010, The Journal of clinical investigation.

[43]  W. Tan,et al.  Functional evaluation of missense variations in the human MAD1L1 and MAD2L1 genes and their impact on susceptibility to lung cancer , 2010, Journal of Medical Genetics.

[44]  Kevin P. Murphy,et al.  SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors , 2010, Bioinform..

[45]  U. Pannicke,et al.  Mutations affecting the secretory COPII coat component SEC23B cause congenital dyserythropoietic anemia type II , 2009, Nature Genetics.

[46]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[47]  C. Bokemeyer,et al.  Blood outgrowth endothelial cells from chronic myeloid leukaemia patients are BCR/ABL1 negative , 2008, British journal of haematology.

[48]  Shulan Tian,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[49]  C. Eaves,et al.  Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. , 2007, Journal of the National Cancer Institute.

[50]  M. Gasparetto,et al.  Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies , 2007, Leukemia.

[51]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[52]  S. Liyanarachchi,et al.  Prognostic impact of MAD1L1 promoter hypermethylation in advanced ovarian cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Hongyue Dai,et al.  Gene expression changes associated with progression and response in chronic myeloid leukemia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Geert J. P. L. Kops,et al.  On the road to cancer: aneuploidy and the mitotic checkpoint , 2005, Nature Reviews Cancer.

[55]  R. Müller,et al.  Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol , 2005, Oncogene.

[56]  Q. Han,et al.  Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics. , 2005, Blood.

[57]  H. Cavé,et al.  Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.

[58]  Eric Deutsch,et al.  Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. , 2003, Blood.

[59]  Rey-Huei Chen,et al.  Spindle checkpoint requires Mad1-bound and Mad1-free Mad2. , 2002, Molecular biology of the cell.

[60]  B. Johansson,et al.  Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia , 2002, Acta Haematologica.

[61]  S. Dirnhofer,et al.  Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells , 2000, The Lancet.

[62]  Atique U. Ahmed,et al.  Mutator phenotype of BCR – ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase β , 1999, Oncogene.

[63]  M Mabry,et al.  RREB-1, a novel zinc finger protein, is involved in the differentiation response to Ras in human medullary thyroid carcinomas , 1996, Molecular and cellular biology.

[64]  M. Deininger.  Diagnosing and managing advanced chronic myeloid leukemia. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[65]  Claude-Alain H. Roten,et al.  Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..

[66]  F. Mitelman.  The cytogenetic scenario of chronic myeloid leukemia. , 1993, Leukemia & lymphoma.